Berotralstat for the prophylaxis of hereditary angioedema-Real-world evidence data from the United Kingdom

doi:10.1111/all.15641

. 2023 May;78(5):1380-1383.

doi: 10.1111/all.15641. Epub 2023 Jan 24.

Berotralstat for the prophylaxis of hereditary angioedema-Real-world evidence data from the United Kingdom

Manisha Ahuja¹, Anthony Dorr², Eniola Bode³, Anne P R Boulton⁴, Matthew Buckland², Samuel Chee⁵, Claire Dalley⁶, Sarah Denman⁷, Anjali Ekbote⁸, Shuayb Elkhalifa⁵, Tariq El-Shanawany⁹, Efrem Eren¹⁰, Archana Herwadkar¹¹, Tomaz Garcez⁵, Harichandana Ghanta¹⁰, Alexandros Grammatikos¹², Sofia Grigoriadou², Rashmi Jain¹³, Lorena Lorenzo², Ania Manson⁴, Emily Moon⁵, Sai Murng¹⁴, Aveen Murphy², Leman Mutlu⁸, Nicholas Peters¹³, Kavitha Sooriyakumar⁸, Catherine Stroud¹⁵, Katie Townsend², Robert L Yellon⁴, Patrick Yong¹⁶, Sorena Kiani-Alikhan²

Affiliations

¹ Royal Victoria Infirmary, Newcastle upon Tyne Hospitals, Newcastle upon Tyne, UK.
² Barts Health NHS Trust, London, UK.
³ Leeds Teaching Hospitals, NHFT, Leeds, UK.
⁴ Cambridge University Hospitals NHSFT, Cambridge, UK.
⁵ Manchester University NHS Foundation Trust, Manchester, UK.
⁶ Gloucestershire Hospitals NHSFT, Gloucester, UK.
⁷ Leeds Teaching Hospitals, NHSF, Leeds, UK.
⁸ University Hospitals Birmingham NHSFT, Birmingham, UK.
⁹ Cardiff and Vale UHB, Cardiff, UK.
¹⁰ University Hospital Southampton NHS Foundation Trust, Southampton, UK.
¹¹ Northern Care Alliance NHS Foundation Trust, Manchester, UK.
¹² North Bristol Hospitals NHSFT, Bristol, UK.
¹³ Oxford University Hospitals, Oxford, UK.
¹⁴ St Helier University Hospitals, Carshalton, Morden, UK.
¹⁵ Newcastle upon Tyne Hospitals NHSFT, Newcastle upon Tyne, UK.
¹⁶ Frimley Health NHSFT, Frimley, UK.

PMID: 36609839
DOI: 10.1111/all.15641

Berotralstat for the prophylaxis of hereditary angioedema-Real-world evidence data from the United Kingdom

Manisha Ahuja et al. Allergy. 2023 May.

. 2023 May;78(5):1380-1383.

doi: 10.1111/all.15641. Epub 2023 Jan 24.

Authors

Affiliations

¹ Royal Victoria Infirmary, Newcastle upon Tyne Hospitals, Newcastle upon Tyne, UK.
² Barts Health NHS Trust, London, UK.
³ Leeds Teaching Hospitals, NHFT, Leeds, UK.
⁴ Cambridge University Hospitals NHSFT, Cambridge, UK.
⁵ Manchester University NHS Foundation Trust, Manchester, UK.
⁶ Gloucestershire Hospitals NHSFT, Gloucester, UK.
⁷ Leeds Teaching Hospitals, NHSF, Leeds, UK.
⁸ University Hospitals Birmingham NHSFT, Birmingham, UK.
⁹ Cardiff and Vale UHB, Cardiff, UK.
¹⁰ University Hospital Southampton NHS Foundation Trust, Southampton, UK.
¹¹ Northern Care Alliance NHS Foundation Trust, Manchester, UK.
¹² North Bristol Hospitals NHSFT, Bristol, UK.
¹³ Oxford University Hospitals, Oxford, UK.
¹⁴ St Helier University Hospitals, Carshalton, Morden, UK.
¹⁵ Newcastle upon Tyne Hospitals NHSFT, Newcastle upon Tyne, UK.
¹⁶ Frimley Health NHSFT, Frimley, UK.

PMID: 36609839
DOI: 10.1111/all.15641

No abstract available

PubMed Disclaimer

Cited by

A Retrospective Analysis of Long-Term Prophylaxis with Berotralstat in Patients with Hereditary Angioedema and Acquired C1-Inhibitor Deficiency-Real-World Data.
Johnson F, Stenzl A, Hofauer B, Heppt H, Ebert EV, Wollenberg B, Lochbaum R, Hahn J, Greve J, Trainotti S. Johnson F, et al. Clin Rev Allergy Immunol. 2023 Dec;65(3):354-364. doi: 10.1007/s12016-023-08972-2. Epub 2023 Nov 2. Clin Rev Allergy Immunol. 2023. PMID: 37914894 Free PMC article. Review.
Berotralstat in hereditary angioedema due to C1 inhibitor deficiency: first real-world evidence from a Canadian center.
Srinivasan C, Ritchie B, Adatia A. Srinivasan C, et al. Front Immunol. 2024 Jan 22;15:1339421. doi: 10.3389/fimmu.2024.1339421. eCollection 2024. Front Immunol. 2024. PMID: 38318176 Free PMC article.
Berotralstat for hereditary angioedema with C1 inhibitor deficiency: a practical guide for clinicians.
Adatia A, Magerl M. Adatia A, et al. Front Immunol. 2024 Oct 8;15:1442671. doi: 10.3389/fimmu.2024.1442671. eCollection 2024. Front Immunol. 2024. PMID: 39439790 Free PMC article. No abstract available.
Hereditary Angioedema Attacks in Patients Receiving Long-Term Prophylaxis: A Systematic Review.
Longhurst HJ, Cancian M, Grivcheva-Panovska V, Koleilat M, Magerl M, Savic S, Stobiecki M, Tachdjian R, Healy B, Yea CM, Audhya PK, Bouillet L. Longhurst HJ, et al. Clin Rev Allergy Immunol. 2024 Dec;67(1-3):83-95. doi: 10.1007/s12016-024-09006-1. Epub 2024 Nov 7. Clin Rev Allergy Immunol. 2024. PMID: 39508959 Free PMC article. Review.

References

REFERENCES

1. Farkas H, Stobiecki M, Peter J, et al. Long-term safety and effectiveness of berotralstat for hereditary angioedema: the open-label APeX-S study. Clin Transl Allergy. 2021;11(4):e12035.
1. [Withdrawn] Berotralstat: Treatment protocol: Information for healthcare professionals [Internet]. GOV.UK. 2022 [cited 10 April 2022]. https://www.gov.uk/government/publications/berotralstat-in-the-treatment...
1. Johnston D, Banerji A, Riedl M, et al. P154 berotralstat improves patient-reported quality of life through 48 weeks in the phase 3 apex-2 trial. Ann Allergy Asthma Immunol. 2020;125(5):S22.
1. Wedner H, Aygören-Pürsün E, Bernstein J, et al. Randomized trial of the efficacy and safety of berotralstat (BCX7353) as an oral prophylactic therapy for hereditary angioedema: results of APeX-2 through 48 weeks (part 2). J Allergy Clin Immunol Pract. 2021;9(6):2305-2314.e4.
1. Bernstein J, Zuraw B, Aygoren-Pursun E, et al. Oral prophylaxis with berotralstat (BCX7353) reduces use of standard of care (SOC) on-demand medication in patients with hereditary angioedema (HAE): APeX-2 study results. J Allergy Clin Immunol. 2020;145(2):AB106.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley

[1] Farkas H, Stobiecki M, Peter J, et al. Long-term safety and effectiveness of berotralstat for hereditary angioedema: the open-label APeX-S study. Clin Transl Allergy. 2021;11(4):e12035.

[2] Farkas H, Stobiecki M, Peter J, et al. Long-term safety and effectiveness of berotralstat for hereditary angioedema: the open-label APeX-S study. Clin Transl Allergy. 2021;11(4):e12035.

[3] [Withdrawn] Berotralstat: Treatment protocol: Information for healthcare professionals [Internet]. GOV.UK. 2022 [cited 10 April 2022]. https://www.gov.uk/government/publications/berotralstat-in-the-treatment...

[4] [Withdrawn] Berotralstat: Treatment protocol: Information for healthcare professionals [Internet]. GOV.UK. 2022 [cited 10 April 2022]. https://www.gov.uk/government/publications/berotralstat-in-the-treatment...

[5] Johnston D, Banerji A, Riedl M, et al. P154 berotralstat improves patient-reported quality of life through 48 weeks in the phase 3 apex-2 trial. Ann Allergy Asthma Immunol. 2020;125(5):S22.

[6] Johnston D, Banerji A, Riedl M, et al. P154 berotralstat improves patient-reported quality of life through 48 weeks in the phase 3 apex-2 trial. Ann Allergy Asthma Immunol. 2020;125(5):S22.

[7] Wedner H, Aygören-Pürsün E, Bernstein J, et al. Randomized trial of the efficacy and safety of berotralstat (BCX7353) as an oral prophylactic therapy for hereditary angioedema: results of APeX-2 through 48 weeks (part 2). J Allergy Clin Immunol Pract. 2021;9(6):2305-2314.e4.

[8] Wedner H, Aygören-Pürsün E, Bernstein J, et al. Randomized trial of the efficacy and safety of berotralstat (BCX7353) as an oral prophylactic therapy for hereditary angioedema: results of APeX-2 through 48 weeks (part 2). J Allergy Clin Immunol Pract. 2021;9(6):2305-2314.e4.

[9] Bernstein J, Zuraw B, Aygoren-Pursun E, et al. Oral prophylaxis with berotralstat (BCX7353) reduces use of standard of care (SOC) on-demand medication in patients with hereditary angioedema (HAE): APeX-2 study results. J Allergy Clin Immunol. 2020;145(2):AB106.

[10] Bernstein J, Zuraw B, Aygoren-Pursun E, et al. Oral prophylaxis with berotralstat (BCX7353) reduces use of standard of care (SOC) on-demand medication in patients with hereditary angioedema (HAE): APeX-2 study results. J Allergy Clin Immunol. 2020;145(2):AB106.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Berotralstat for the prophylaxis of hereditary angioedema-Real-world evidence data from the United Kingdom

Affiliations

Berotralstat for the prophylaxis of hereditary angioedema-Real-world evidence data from the United Kingdom

Authors

Affiliations

Similar articles

Cited by

References

REFERENCES

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Similar articles

Cited by

References

REFERENCES

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources